A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 819 participants.

Also called NCT02607306

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 819 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02607306
Main results
  • Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial Diabetes, obesity & metabolism, 2019-12 DOI, PubMed 31407845, PMC6899795 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02607306. Randomized; no masking; primary purpose treatment. Start 2015-11-18 (actual); primary completion 2017-12-15 (actual). Results posted on 2019-07-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
Acronym
DUAL™ I Japan
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec/liraglutide
Intervention (Drug)
insulin degludec
Intervention (Drug)
liraglutide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02607306
Content hash
45737b2a2d2aee6e77e535384535c9d576c916ac807c6adeb92cbafb10a78fe8